According to our data, PC patients treated with LHRH antagonists may experience less body composition changes due to lower FSH residual values (Klotz et al., 2008; Margel et al., 2019; Abufaraj et al., 2021). This evidence concerns the gene BRD2 and pachyonychia congenita.